Strong COVID vaccine sales help Moderna beat fourth quarter revenue estimates
The vaccine maker reported fourth-quarter revenue of 678 million dollars today. Strong US sales of its COVID-19 shot helped the company beat analyst targets.
Insights:
Moderna, Inc. reported fourth-quarter revenue of $678 million on February 13, 2026, beating Wall Street estimates of $626.1 million as calculated by LSEG. The quarterly performance was driven in part by stronger-than-expected sales of the company’s COVID-19 vaccine in the US 
US. This revenue beat is significant as the company works to close a revenue gap following the decline in pandemic-era demand for its products.
US. This revenue beat is significant as the company works to close a revenue gap following the decline in pandemic-era demand for its products.
